Skip to main content

Table 3 Change in loss of ambulation

From: The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review

Country/countries Name of subgroup First author & publication year Sample size Mean age Loss of ambulation (%) Time point for follow up Loss of Ambulation (n)@FU Loss of ambulation (%)@FU
Italy Ambulatory <350 m(6MWT), <7y Pane, 2014 [34] 9 5.8 0 3y 2 22.22
Ambulatory ≥350 m(6MWT), <7y 19 6.16 1 5.26
Ambulatory <350 m(6MWT), ≥7y 25 9.87 16 64.00
Ambulatory ≥350 m(6MWT), ≥7y 43 8.9 5 11.63
Ambulatory-boys 96 NR 1y 3 3.00
2y 16 17.00
3y 27 29.00
Italy; Belgium Ambulatory ≥100 m Pane, 2014 [42] 191 7.9 1y 4 2.10
NR Boys Mah, 2012 [44] 340 12.0 43 194 57.06
Sweden All DMD Soderpalm, 2012 [45] 24 NR 17 4y 9 38.00
UK Boys Ricotti, 2012 [47] 400 NR 7Y NR Median loss of ambulation was 14 years in Daily versus 12 years in Intermittent prednisolone